Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,6-diaminoquinazolin-4-ol is a synthetic small molecule belonging to the quinazoline family of heterocyclic aromatic compounds. Its structure features a quinazoline core substituted with amino groups at positions 2 and 6 and a hydroxyl group at position 4. This compound has been primarily studied as an experimental chemical entity rather than as an approved pharmaceutical drug. Quinazoline derivatives are known for their broad pharmacological activities—including antimalarial and kinase inhibitory properties—but there is no evidence that this specific compound has reached clinical development or approval for any indication[1][8]. It is mainly used in research settings to explore the biological activity of quinazolines or as an intermediate in medicinal chemistry[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,6-diaminoquinazolin-4-ol.